首页> 美国政府科技报告 >Riboswitch-Mediated Aptamer Binding for Imaging and Therapy (RABIT): A Novel Technique to Selectively Target an Intracellular Ligand Specific for Ovarian Cancer.
【24h】

Riboswitch-Mediated Aptamer Binding for Imaging and Therapy (RABIT): A Novel Technique to Selectively Target an Intracellular Ligand Specific for Ovarian Cancer.

机译:用于成像和治疗的核糖开关介导的适体结合(RaBIT):选择性靶向卵巢癌特异性细胞内配体的新技术。

获取原文

摘要

We have proposed a novel technique to image and treat ovarian cancer with very high specificity, low background for imaging and low toxicity for therapy. We will make a riboswitch consisting of two aptamers and a sensor region that can hybridize with the specific intracellular ovarian cancer cell marker, VICKZ. The target for the first aptamer, EpCAM, is a surface antigen that is up-regulated in cancer cells. During cellular recycling, EpCAM will carry the attached riboswitch into the cell. Inside the cell, the riboswitch will interact with VICKZ mRNA. This interaction will change the conformation of the riboswitch to expose a second aptamer in the correct conformation to bind an administered radioactive agent which rapidly enters and exits the ovarian cancer cells, eg. antipyrine. Depending on the radioactive isotope attached to the agent, the ovarian cancer cells will be either imaged (123I) or killed (131I). We have successfully made both DNA and RNA aptamers to antipyrine, the 2nd proposed aptamer, and have been working on isolating aptamers to iodoantipyrine. We have also accomplished the important task of introducing a large portion of the eventual riboswitch into the cell interior where it appears to binds selectively to the target cancer cell marker, VICKZ mRNA.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号